141 related articles for article (PubMed ID: 3711669)
1. Murine melanoma-specific tumor rejection activity elicited by a purified, melanoma-associated antigen.
Hearing VJ; Gersten DM; Montague PM; Vieira WD; Galetto G; Law LW
J Immunol; 1986 Jul; 137(1):379-84. PubMed ID: 3711669
[TBL] [Abstract][Full Text] [Related]
2. A unique tumor rejection antigen from the S91 murine malignant melanoma.
Law LW; Vieira WD; Kameyama K; Hearing VJ
Cancer Res; 1987 Nov; 47(22):5841-5. PubMed ID: 3664485
[TBL] [Abstract][Full Text] [Related]
3. Serological characterization of a shared melanoma-associated antigen of mouse melanomas: relationship to the B700 glycoprotein.
DeLeo AB; Hearing VJ; Vieira WD; Law LW
Melanoma Res; 1991; 1(2):133-40. PubMed ID: 1668533
[TBL] [Abstract][Full Text] [Related]
4. Multiple antigens related to the major envelope glycoprotein of murine leukemia virus expressed on B16 melanoma cells as targets of host immune response.
Stackpole CW; Demsey A
Invasion Metastasis; 1984; 4(1):28-46. PubMed ID: 6329988
[TBL] [Abstract][Full Text] [Related]
5. Demonstration of B700 cross-reactive antigens on human and other animal melanomas.
Gersten DM; Hearing VJ
Pigment Cell Res; 1988; 1(6):434-8. PubMed ID: 3237611
[TBL] [Abstract][Full Text] [Related]
6. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
7. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
8. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
[TBL] [Abstract][Full Text] [Related]
9. Identification of immunogenic B16 melanoma-associated antigens.
Johnston D; Schachne JP; Bystryn JC
J Biol Response Mod; 1987 Apr; 6(2):108-20. PubMed ID: 3585408
[TBL] [Abstract][Full Text] [Related]
10. Syngeneic monoclonal antibodies to B16 melanoma viral antigens.
Rappaport I; Alterman AL; Braverman S; Stackpole CW
Cancer Res; 1987 Oct; 47(20):5391-6. PubMed ID: 3652042
[TBL] [Abstract][Full Text] [Related]
11. Production of monoclonal antibodies against the B700 murine melanoma antigen and their antimetastatic properties.
Gersten DM; Moody D; Vieira WD; Law LW; Hearing VJ
Biochim Biophys Acta; 1992 Feb; 1138(2):109-14. PubMed ID: 1540656
[TBL] [Abstract][Full Text] [Related]
12. Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma-associated antigens.
Bystryn JC
J Immunol; 1978 Jan; 120(1):96-101. PubMed ID: 627729
[TBL] [Abstract][Full Text] [Related]
13. The intracellular association of B700 and B50 murine melanoma antigens and their role in tumor rejection.
Gersten DM; Williams LJ; Moody D; Montague PM; Law LW; Hearing VJ
Int J Cancer; 1989 Mar; 43(3):497-500. PubMed ID: 2925280
[TBL] [Abstract][Full Text] [Related]
14. Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice.
Falcioni R; Kennel SJ; Giacomini P; Zupi G; Sacchi A
Cancer Res; 1986 Nov; 46(11):5772-8. PubMed ID: 3756921
[TBL] [Abstract][Full Text] [Related]
15. Extraction of immunogenic and suppressogenic antigens from variants of B16 melanoma exhibiting low or high metastatic potentials.
LeGrue SJ; Hearn DR
Cancer Res; 1983 Nov; 43(11):5106-11. PubMed ID: 6616449
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody production to a B16 melanoma associated antigen.
Tomita Y; Montague PM; Hearing VJ
Int J Cancer; 1985 Apr; 35(4):543-7. PubMed ID: 3886561
[TBL] [Abstract][Full Text] [Related]
17. Cross-reactivity between murine melanoma antigen B700 and a human melanoma-associated antigen (M-66) recognized by autologous antibody: evidence suggesting shared epitopes.
Toporowicz A; Gersten DM; Hearing VJ; Brown WE; Vlock DR
Biochim Biophys Acta; 1993 Aug; 1182(1):51-6. PubMed ID: 7688577
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
19. Afferent and efferent specificity in the induction and elicitation of parental cross-protective immunity by an immunogenic murine tumor variant: associative recognition of a unique tumor-specific antigen on somatic cell hybrids.
LeGrue SJ; Ananthaswamy HN; Simcik WJ
Cancer Res; 1989 Sep; 49(17):4747-51. PubMed ID: 2474372
[TBL] [Abstract][Full Text] [Related]
20. The expression of tumor-associated antigens in primary and metastatic human malignant melanoma.
Brüggen J; Bröcker EB; Suter L; Redmann K; Sorg C
Behring Inst Mitt; 1984 May; (74):19-23. PubMed ID: 6477352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
